| Full text | |
| Author(s): |
João Calvino Soares de Oliveira
[1]
;
Alexandre Moura dos Santos
[2]
;
Mariana Freitas de Aguiar
[3]
;
Jucier Gonçalves Junior
[4]
;
Alexandre Wagner Silva de Souza
[5]
;
Rosa Maria R. Pereira
;
Samuel Katsuyuki Shinjo
[7]
Total Authors: 7
|
| Affiliation: | [1] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil
[2] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil
[3] Universidade Federal de São Paulo. Divisão de Reumatologia - Brasil
[4] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil
[5] Universidade Federal de São Paulo. Divisão de Reumatologia - Brasil
[7] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil
Total Affiliations: 7
|
| Document type: | Journal article |
| Source: | Arquivos Brasileiros de Cardiologia; v. 120, n. 1 2023-01-09. |
| Abstract | |
Abstract Background Few studies have assessed elderly patients with Takayasu’s arteritis (TAK). Objectives To evaluate the progression of TAK in different age groups and its possible effects on drug treatment and disease activity. Methods This cross-sectional and retrospective cohort study included 66 TAK patients. Patients were interviewed and data of the 12 preceding months were collected from electronic medical records. The patients were divided into four quartiles according to current age and compared for clinical and laboratory data, treatment, comorbidities, disease status, and functional status. Statistical significance was set at p<0.05. Results The groups were Q1(22-36 years, n=16), Q2(37-42 years, n=18), Q3(43-49 years, n=17), and Q4(51-66 years, n=15). The frequency of patients with disease activity, fatigue, comorbidities and vascular impairments, and the TAK disease extent index were also comparable between the groups. With age, disease duration was longer (p=0.001), fewer patients used prednisone (Q1:43.8%, Q2:33.3%, Q3:11.8%, and Q4:6.7%; p=0.049) and immunosuppressive drugs [Q1:100.0%, Q2:66.7%, Q3:58.8%, and Q4:46.7%; Q1 versus Q3 (p=0.043), and Q1 versus Q4 (p=0.005) in post-hoc analyses], and patients had greater functional status impairment (Q2 versus Q3, p=0.003). In addition, the levels of disease damage, new TAK symptoms, and complications in the preceding 12 months were not different between the groups. Conclusions Older patients with TAK require minimal drug treatment, and have greater impairment of functional status, which may be attributed to aging-related factors. (AU) | |
| FAPESP's process: | 19/11776-6 - Impact and safety of noninvasive cerebral neuromodulation in patients with systemic autoimmune diseases: double-blind, randomized, placebo-controlled study |
| Grantee: | Samuel Katsuyuki Shinjo |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 20/10691-4 - Efficiency and safety of transcranial direct current stimulation in the treatment of fatigue in patients with Primary Systemic Vasculitis: clinical trial, randomized, double-blind and sham-controlled |
| Grantee: | Alexandre Moura dos Santos |
| Support Opportunities: | Scholarships in Brazil - Doctorate |